Diabetes Care, Vol 19, Issue 10 1051-1061, Copyright © 1996 by American Diabetes Association

ARTICLES

An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group

RA Rodby, LM Firth and EJ Lewis
Department of Medicine, Rush Medical College, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illionis 60612, USA. rrodby@earthlink.net

OBJECTIVE: The results of a recent clinical trial. The Effect of ACE inhibition on Diabetic Nephropathy, demonstrated that captopril reduced the rate of renal failure, end-stage renal disease (ESRD), and death in patients with IDDM and nephropathy. The purpose of this study was to determine the cost-benefit and cost-effectiveness of captopril as a therapy in patients with IDDM as well as the potential savings for all patients with diabetes and nephropathy. RESEARCH DESIGN AND METHODS: We used the results from a randomized, placebo-controlled trial comparing captopril (207 patients) with placebo (202 patients), whose purpose was to determine whether captopril has kidney-protecting properties independent of its effect on blood pressure in diabetic nephropathy to develop a model of medical treatment for patients before progression to ESRD. To model the course of illness after progression to ESRD and to extend the model to patients with NIDDM, we used data from the U.S. Renal Data System and published literature. Medical resource cost data were based predominantly upon Medicare reimbursement levels, published wholesale drug prices, and surveying health care providers. The economic model uses a payer perspective to estimate direct cost. The cost to society (indirect cost) associated with lost patient productivity due to ESRD was also estimated. Using this information, we predicted the costs incurred annually and over a lifetime if patients with IDDM and NIDDM and overt nephropathy were treated with either placebo or captopril. We also constructed a model of the overall prevalence of diabetic nephropathy to estimate the aggregate savings in total U.S. health care expenditures. RESULTS: Treatment with captopril resulted in an absolute direct cost savings or benefit of $32,550 per patient with IDDM over the course of a lifetime compared to treatment with placebo. For patients with NIDDM, the direct cost savings totaled $9,900 per patient. Absolute savings were found for indirect costs as well: $84,390 per patient with IDDM and $45,730 per patient with NIDDM. If captopril therapy were initiated in 1995 for patients with either IDDM or NIDDM and nephropathy, the aggregate health care cost savings (i.e. direct cost savings alone) would be $189 million a year for the year 1999 and $475 million a year in 2004, the present value of cumulative health care cost savings for these 10 years would be $2.4 billion. CONCLUSIONS: The use of captopril in diabetic nephropathy will provide significant savings in health care costs; in addition, it will result in savings in indirect cost, which reflects the broader societal benefit.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. T. Ackermann, T. J. Thompson, J. V. Selby, M. M. Safford, M. Stevens, A. F. Brown, and K.M. V. Narayan Is the Number of Documented Diabetes Process-of-Care Indicators Associated With Cardiometabolic Risk Factor Levels, Patient Satisfaction, or Self-Rated Quality of Diabetes Care?: The Translating Research into Action for Diabetes (TRIAD) study. Diabetes Care, September 1, 2006; 29(9): 2108 - 2113. [Abstract] [Full Text] [PDF]

				M. Ravera, M. Re, and S. Vettoretti Economic Evaluation of Angiotensin Receptor Blockers in Type 2 Diabetes, Hypertension, and Nephropathy J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S44 - S48. [Abstract] [Full Text] [PDF]

				A. B. Rosen, M. B. Hamel, M. C. Weinstein, D. M. Cutler, A. M. Fendrick, and S. Vijan Cost-Effectiveness of Full Medicare Coverage of Angiotensin-Converting Enzyme Inhibitors for Beneficiaries with Diabetes Ann Intern Med, July 19, 2005; 143(2): 89 - 99. [Abstract] [Full Text] [PDF]

				A. J. Palmer, D. M. D. Tucker, W. J. Valentine, S. Roze, S. Gabriel, and D. J. Cordonnier Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies Nephrol. Dial. Transplant., June 1, 2005; 20(6): 1103 - 1109. [Abstract] [Full Text] [PDF]

				W. H. Herman, T. J. Hoerger, M. Brandle, K. Hicks, S. Sorensen, P. Zhang, R. F. Hamman, R. T. Ackermann, M. M. Engelgau, R. E. Ratner, et al. The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance Ann Intern Med, March 1, 2005; 142(5): 323 - 332. [Abstract] [Full Text] [PDF]

				A. J. Palmer, L. Annemans, S. Roze, M. Lamotte, P. Lapuerta, R. Chen, S. Gabriel, P. Carita, R. A. Rodby, D. de Zeeuw, et al. Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive Medications Excluding ACE Inhibitors, Other Angiotensin-2 Receptor Antagonists, and Dihydropyridine Calcium Channel Blockers) or Late Irbesartan Treatment in Patients With Type 2 Diabetes, Hypertension, and Renal Disease Diabetes Care, August 1, 2004; 27(8): 1897 - 1903. [Abstract] [Full Text] [PDF]

				K. Abbott, E. Basta, and G. L. Bakris Blood Pressure Control and Nephroprotection in Diabetes J. Clin. Pharmacol., April 1, 2004; 44(4): 431 - 438. [Abstract] [Full Text] [PDF]

				R. C. Carlos, D. A. Axelrod, J. H. Ellis, P. H. Abrahamse, and A. M. Fendrick Incorporating Patient-Centered Outcomes in the Analysis of Cost-Effectiveness: Imaging Strategies for Renovascular Hypertension Am. J. Roentgenol., December 1, 2003; 181(6): 1653 - 1661. [Abstract] [Full Text] [PDF]

				L. L. Ilag, C. L. Martin, B. P. Tabaei, D. J. M. Isaman, R. Burke, D. A. Greene, and W. H. Herman Improving Diabetes Processes of Care in Managed Care Diabetes Care, October 1, 2003; 26(10): 2722 - 2727. [Abstract] [Full Text] [PDF]

				K. J. Craig, K. Donovan, M. Munnery, D. R. Owens, J. D. Williams, and A. O. Phillips Identification and Management of Diabetic Nephropathy in the Diabetes Clinic Diabetes Care, June 1, 2003; 26(6): 1806 - 1811. [Abstract] [Full Text] [PDF]

				W. H. Herman, S. Shahinfar, G. W. Carides, E. J. Dasbach, W. C. Gerth, C. M. Alexander, J. R. Cook, W. F. Keane, and B. M. Brenner Losartan Reduces the Costs Associated With Diabetic End-Stage Renal Disease: The RENAAL study economic evaluation Diabetes Care, March 1, 2003; 26(3): 683 - 687. [Abstract] [Full Text] [PDF]

				A. I Adler, I. M Stratton, H A. W Neil, J. S Yudkin, D. R Matthews, C. A Cull, A. D Wright, R. C Turner, and R. R Holman Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study BMJ, August 12, 2000; 321(7258): 412 - 419. [Abstract] [Full Text]

				G. R. McAnulty, H. J. Robertshaw, and G. M. Hall Anaesthetic management of patients with diabetes mellitus Br. J. Anaesth., July 1, 2000; 85(1): 80 - 90. [Full Text] [PDF]

				W. J. Elliott, D. R. Weir, and H. R. Black Cost-effectiveness of the Lower Treatment Goal (of JNC VI) for Diabetic Hypertensive Patients Arch Intern Med, May 8, 2000; 160(9): 1277 - 1283. [Abstract] [Full Text] [PDF]

				R. A. Rodby, R. D. Rohde, W. R. Clarke, L. G. Hunsicker, D. A. Anzalone, R. C. Atkins, E. Ritz, and E. J. Lewis The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics Nephrol. Dial. Transplant., April 1, 2000; 15(4): 487 - 497. [Abstract] [Full Text] [PDF]

				H. Dean NIDDM-Y in First Nation Children in Canada Clinical Pediatrics, February 1, 1998; 37(2): 89 - 96. [Abstract] [PDF]